Stockscreener 앱 받기
1.82
11.31%
0.185
시간 외 거래:
2.02
0.20
+10.99%
전일 마감가:
$1.635
열려 있는:
$1.68
하루 거래량:
4.92M
Relative Volume:
2.82
시가총액:
$309.29M
수익:
-
순이익/손실:
$-274.18M
주가수익비율:
-0.7181
EPS:
-2.5346
순현금흐름:
$-198.33M
1주 성능:
+2.82%
1개월 성능:
-18.02%
6개월 성능:
+121.52%
1년 성능:
-26.61%
1일 변동 폭
$1.50
$2.0298
1주일 범위
$1.50
$2.0298
52주 변동 폭
$0.611
$3.25
Neumora Therapeutics Inc Stock (NMRA) Company Profile
명칭
Neumora Therapeutics Inc
전화
(857) 760-0900
주소
260 ARSENAL PLACE, SUITE 1, WATERTOWN
NMRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.82 | 277.85M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-01 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-09-16 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-04-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2025-03-10 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Hold |
| 2023-10-10 | 개시 | BofA Securities | Buy |
| 2023-10-10 | 개시 | Guggenheim | Buy |
| 2023-10-10 | 개시 | JP Morgan | Overweight |
| 2023-10-10 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-10 | 개시 | Stifel | Buy |
| 2023-10-10 | 개시 | William Blair | Outperform |
모두보기
Neumora Therapeutics Inc 주식(NMRA)의 최신 뉴스
Neumora outlines 2026 pipeline milestones for neuroscience programs By Investing.com - Investing.com Nigeria
Neumora gains after early-stage trial results for Alzheimer’s product - MSN
Positive Risk-Reward on Neumora as NMRA-511 Emerges as a Differentiated Therapy for Alzheimer’s Agitation, Supporting Buy Rating and $18 Target - TipRanks
Mizuho raises Neumora Therapeutics stock price target on positive trial data - Investing.com Canada
Neumora Therapeutics touts Phase 1B NMRA-511 gains in Alzheimer’s agitation, eyes higher doses - MarketBeat
Neumora shares climb after encouraging Phase 1b results for Alzheimer’s agitation therapy - MSN
Why Is Neumora Therapeutics Stock Gaining Monday?Neumora Therapeutics (NASDAQ:NMRA) - Benzinga
Neumora stock rises after positive Phase 1b data for Alzheimer’s agitation drug - Investing.com Canada
NMRA Surges On Clinically Meaningful Results In Phase 1 Alzheimer's Disease Agitation Study - Nasdaq
Neumora outlines 2026 pipeline milestones for neuroscience programs - Investing.com
Neumora posts trial results for Alzheimer’s drug (NMRA:NASDAQ) - Seeking Alpha
Neumora reports promising Phase 1b results in Alzheimer’s agitation - TipRanks
Neumora Therapeutics Announces Positive Phase 1b Study Results for NMRA-511 - TradingView — Track All Markets
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones - The Manila Times
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation - The Manila Times
New Alzheimer’s treatment candidate eases agitation in early study - Stock Titan
10 Best New Penny Stocks to Invest In - Insider Monkey
RBC Sees Upside Potential in Neumora Therapeutics (NMRA) - Finviz
What analysts say about Neumora Therapeutics Inc stockMid Cap Growth Trends & Free Superior Trading Gains - earlytimes.in
Neumora stock rises after positive Phase 1b data for Alzheimer’s agitation drug By Investing.com - Investing.com South Africa
Momentum Shift: Will Neumora Therapeutics Inc. stock benefit from AI adoptionNew Guidance & Consistent Income Trade Recommendations - moha.gov.vn
Cash Runway Looks Solid, But Is Neumora's Pipeline Ready To Deliver? - RTTNews
Is Neumora Therapeutics Inc. stock resilient to inflation2025 Volatility Report & Fast Gaining Stock Reports - Улправда
Can Neumora Therapeutics Inc. stock beat market expectations this quarterQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - Улправда
Will Neumora Therapeutics Inc. stock benefit from AI adoptionOil Prices & Weekly Setup with High ROI Potential - Улправда
Analyst Calls: How Neumora Therapeutics Inc stock reacts to job market dataIPO Watch & Smart Swing Trading Techniques - moha.gov.vn
Is Neumora Therapeutics Inc. stock a defensive play in 2025July 2025 Pullbacks & AI Powered Market Entry Ideas - DonanımHaber
Will Neumora Therapeutics Inc. stock beat EPS estimates2025 EndofYear Setup & Risk Controlled Stock Pick Alerts - DonanımHaber
Why Neumora Therapeutics Inc. stock could rally in 2025Stop Loss & Stock Portfolio Risk Management - Улправда
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Neumora Therapeutics Earnings Notes - Trefis
Neumora cut to Hold at Stifel after J&J’s VENTURA exit - MSN
MACD Signal: Can Neumora Therapeutics Inc stock beat market expectations this quarterJuly 2025 Update & Verified Chart Pattern Signals - BỘ NỘI VỤ
Neumora Therapeutics upgraded to Outperform from Sector Perform at RBC Capital - MSN
Neumora upgraded at RBC Capital Markets on obesity, Parkinson's asset - MSN
Can Neumora Therapeutics Inc. stock weather global recession2025 Price Action Summary & Free Long-Term Investment Growth Plans - Newser
How Neumora Therapeutics Inc. stock reacts to job market dataQuarterly Trade Review & Free Accurate Trade Setup Notifications - Newser
Is Neumora Therapeutics Inc. stock attractive for ETFsPortfolio Growth Summary & Technical Buy Zone Confirmation - Newser
What momentum indicators show for Neumora Therapeutics Inc. stockGold Moves & Safe Capital Investment Plans - Newser
Neumora Therapeutics (NMRA) Stock Analysis Report | Financials & Insights - Benzinga
Neumora Therapeutics stock rating upgraded by RBC Capital on NLRP3 potential - Investing.com Canada
Neumora Therapeutics Shares Rise After RBC Upgrade - marketscreener.com
Neumora upgraded at RBC Capital Markets on obesity, Parkinson's asset (NMRA:NASDAQ) - Seeking Alpha
Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline - Benzinga
This Chevron Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
RBC Capital Upgrades Neumora Therapeutics (NMRA) - Nasdaq
RBC Upgrades Neumora Therapeutics to Outperform From Sector Perform, Raises Price Target to $7 From $4, Keeps Speculative Risk - marketscreener.com
What drives Neumora Therapeutics Inc stock priceIPO Market Watch & Outstanding Portfolio Tips - earlytimes.in
Neumora Therapeutics Inc (NMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):